Treatment of eye conditions
AssigneeThe University of Birmingham
InventorsZubair Ahmed, Richard Ian Tuxworth
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the treatment of eye conditions, by inhibiting Chk2 kinase. Particular ocular conditions may be associated with neuronal damage/dysfunction in the eye, or neurons in communication with the eye, which may result from, physical trauma, chemical means, infection, inflammation, hypoxia and/or interruption inblood supply, or be due to a neurodegenerative disorder and/or autoimmune disease. The Chk2 inhibitor may be a small molecule, protein, peptide or nucleic acid. Exemplary small molecule Chk2 inhibitors include PV1019, AZD7762, CCT241533, BML-277 or prexasertib.
Claims16
A Chk2 inhibitor for use in a method of preventing or treating an ocular condition.
The Chk2 inhibitor for use according to any one of the preceding claims, wherein the Chk2 inhibitor inhibits expression or activity of Chk2.
The Chk2 inhibitor for use according to any one of the preceding claims, wherein the Chk2 inhibitor is a small molecule, protein, peptide or nucleic acid.
An ophthalmic formulation comprising a Chk2 inhibitor, together with an ophthalmically acceptable excipient therefor.
The ophthalmic formulation according to claim 16 to be administered as an irrigating solution, topically, perioclarly, or intraocularly.
Dependencies are inferred from the claim text.